News >

FDA Approves Gardasil 9 HPV Vaccine for Use Up to Age 45

OncLive Staff
Published: Sunday, Oct 07, 2018

The HPV vaccine Gardasil 9 (HPV 9-valent Vaccine, Recombinant) is now approved by the FDA for use in males and females aged 9 through 45 years.1

The company also noted that “Gardasil 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of Gardasil 9 or Gardasil."

References

  1. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. FDA. Published October 5, 2018. Accessed October 7, 2018. https://bit.ly/2zVRxa9.
  2. FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL®9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases. Merck. Published June 13, 2018. Accessed October 7, 2018. https://bit.ly/2zWvlgo.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x